Literature DB >> 27108615

Malignant, but not benign, intraductal papillary mucinous neoplasm preferentially associates with prior extrapancreatic malignancies.

Takaharu Kato1, Sergio Alonso2, Hiroshi Noda1, Yasuyuki Miyakura1, Shingo Tsujinaka1, Masaaki Saito1, Yuta Muto1, Taro Fukui1, Kosuke Ichida1, Yuji Takayama1, Fumiaki Watanabe1, Nao Kakizawa1, Manuel Perucho2, Toshiki Rikiyama1.   

Abstract

Intraductal papillary mucinous neoplasm (IPMN) has been associated with a high incidence of extrapancreatic malignancies (EPMs). However, it is controversial whether IPMN is prognostic for EPM. We aimed to help clarify the issue studying this association in patients with histologically proven IPMN. We reviewed 51 surgically resected IPMNs in Saitama Medical Center, Jichi Medical University between January 1991 and June 2012. Mean follow-up was 63.7±47.8 months. The observed EPM incidence was compared with the expected incidence of cancer in Japan. Of the 51 IPMNs, 14 were malignant and the rest benign. Seventeen EPMs developed in 15 patients (29.4%), nine of which occurred prior to IPMN diagnosis. For all IPMNs, the standardized incidence ratio (SIR) was significantly increased for the six types of reported EPMs (SIR=2.18, CI=1.31-3.42, P=0.004). Benign IPMNs showed no association with EPMs (SIR=0.92, CI=0.43-1,76, P=0.87). In contrast, malignant IPMNs showed a higher association (SIR=3.83, CI=1.87-7.03, P=0.0009). However, the association was mostly due to the prior EPMs, as removal of metachronous EPMs had no significant effect (SIR=3.63, CI=1.59-7.17, P=0.005). Thus, only malignant IPMNs drive the significant association with prior EPMs, showing a near 4-fold increased incidence compared to the general Japanese population. Histological characterization of IPMNs may offer clinical value for EPM patient management. We hypothesize that these observations may be explained if some patients with EPMs present a higher risk to develop IPMNs (and vice versa), possibly resulting from an uncharacterized multiple cancer predisposition condition.

Entities:  

Mesh:

Year:  2016        PMID: 27108615     DOI: 10.3892/or.2016.4755

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Increased prevalence of colorectal neoplasia in patients with intraductal papillary mucinous neoplasms.

Authors:  Dana Zelnik Yovel; Lior Bear; Erez Scapa; Mati Shnell; Iddo Bar Yishay; Nir Bar; Tomer ZIv Baran; Fadi Younis; Adam Phillips; Nir Lubezky; Oren Shibolet; Dana Ben-Ami Shor
Journal:  Therap Adv Gastroenterol       Date:  2022-06-16       Impact factor: 4.802

Review 2.  Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives.

Authors:  Ijm Levink; M J Bruno; D L Cahen
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.